Xcout Intel
ORYZON GENOMICS competitors & alternatives
The 12 closest competitors and alternatives to ORYZON GENOMICS among biotech companies — ranked by similarity to what ORYZON GENOMICS actually does, not by market-cap band.
Subscribe to see ORYZON GENOMICS’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ORYZON GENOMICS
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's pipeline features two lead compounds in Phase II clinical trials: iadademstat (ORY-1001), a selective LSD1 inhibitor targeting oncology, and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for CNS applications, addressing neurological and psychiatric conditions. Furthermore, ORY-3001, another LSD1 inhibitor, is currently in preclinical development for a range of non-cancer-related illnesses. Founded in 2000, Oryzon Genomics S.A. is headquartered in Cornellà de Llobregat, Spain.
ORYZON GENOMICS at a glance
ORYZON GENOMICS is a biotech company headquartered in Cornellà de Llobregat, Spain. It is publicly listed (0RDB) with a market capitalisation of $261.6M. Xcout tracks 6 named people at ORYZON GENOMICS, including Carlos Buesa (President (Executive Director)).
ORYZON GENOMICS leadership
- Carlos BuesaPresident (Executive Director)
- Konstantinos AlatarisBoard Member (Independent Director)
- Luis Sánchez QuintanaBoard Member (Independent Director)
- Manuel López-FigueroaBoard Member (Independent Director)
- Montserrat VendrellBoard Member (Independent Director)
- Pierre BeaurangBoard Member (Independent Director)
Top 12 ORYZON GENOMICS competitors
Ranked by semantic similarity — how close each company is to ORYZON GENOMICS by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Similar biotech company
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotech company
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Similar biotech company
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Biotechnology
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Similar biotech company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotechnology
Celyad Oncology is a biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, focused on the development of innovative therapies.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotechnology
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar biotech company
Rznomics is a South Korean biotechnology company developing RNA-based gene therapies using a trans-splicing ribozyme platform. Its programs are focused primarily on therapeutic applications in cancer and other serious diseases, serving patients through prospective drug-development and clinical partnerships.
Biotechnology
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company headquartered in Morristown, New Jersey, focused on developing precision therapies for genetically defined cancers.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ORYZON GENOMICS and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ORYZON GENOMICSand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →